Semaglutide
Chronic weight management and other labeled uses vary by product
Evidence: Strong FDA-reviewed clinical evidence
Administration: Injection or oral; product-specific
Score 9.1/10Read Review →Evidence and regulatory context for peptide-based treatments connected to metabolic health.
Tirzepatide
Chronic weight management; other indications depend on product
Evidence: Strong FDA-reviewed clinical evidence
Administration: Weekly injection
Score 9.1/10Read Review →Liraglutide
Weight management or type 2 diabetes, depending on product
Evidence: Strong FDA-reviewed clinical evidence
Administration: Daily injection
Score 8.7/10Read Review →Glucagon
Emergency treatment of severe hypoglycemia
Evidence: Strong product-specific evidence
Administration: Nasal or injection; product-specific
Score 9.1/10Read Review →MOTS-C
Investigational metabolic and longevity research
Evidence: Primarily preclinical
Administration: No approved route
Read Review →Established / approved options
Semaglutide, tirzepatide, liraglutide, and glucagon have product-specific roles relevant to metabolic health or severe hypoglycemia.
Being researched
MOTS-C is being researched, but FDA approval and adequate human safety evidence are lacking.
How to use this page
Established options appear before experimental compounds. Goal relevance never overrides regulatory status or evidence quality.
Next step
Open the relevant treatment review for sources, risks, contraindications, and evidence gaps.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.